Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10969 | 0.86 | MEN1 (0.33) | ALDH1A1KDM4EKMT2ALMNAMEN1 | |
| SCHEMBL296412 | 0.86 | — | — | |
| SCHEMBL11133 | 0.84 | HRH3 (0.36) | ALDH1A1KDM4EHRH3 | |
| SCHEMBL423536 | 0.79 | — | — | |
| SCHEMBL295704 | 0.75 | — | — | |
| SCHEMBL357824 | 0.75 | — | — | |
| SCHEMBL12311431 | 0.75 | DRD2 (0.36) | DRD2DRD3SIGMAR1 | |
| SCHEMBL476371 | 0.75 | ALOX15 (0.57) | SIGMAR1 | |
| SCHEMBL3971866 | 0.74 | ALDH1A1 (0.65) | ALDH1A1KDM4EKMT2ALMNAHTT | |
| SCHEMBL13833159 | 0.74 | ALDH1A1 (0.65) | ALDH1A1KDM4EKMT2ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203457-B1 | DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2014-03-05 | — | — | EP | disclosed |
| US-8357235-B2 | Inkjet ink composition and inkjet recording method | FUJIFILM CORPORATION (JP) | 2013-01-22 | — | — | US | disclosed |
| US-8283005-B2 | Inkjet recording medium and method of manufacturing the same | FUJIFILM CORPORATION (JP) | 2012-10-09 | — | — | US | disclosed |
| EP-1147104-B1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA (US) | 2012-03-14 | — | — | EP | disclosed |
| US-8084106-B2 | Inkjet recording medium and method of manufacturing the same | FUJIFILM CORPORATION (JP) | 2011-12-27 | — | — | US | disclosed |
| US-8067620-B2 | Cis-adamantane-2-spiro-3'-8'-[4'-[2'-(4'-morpholinyl)ethoxy]phenyl]-1',2',4'-trioxaspiro[4.5]decane mesylate (OZ439); nonneurotoxic; pharmacokinetics; stability; oral absorption; bioavailability; anticarcinogenic agents; single-dose cure;antiprotozoan agents; parasiticides; schistosomiasis; | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2011-11-29 | — | — | US | disclosed |
| US-20100242791-A1 | INKJET INK COMPOSITION AND INKJET RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100231670-A1 | SET FOR INK JET RECORDING, AND INK JET RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2203457-A2 | DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS | Medicines For Malaria Venture MMV (CH) | 2010-07-07 | — | — | EP | disclosed |
| US-20100080908-A1 | INK SET AND METHOD FOR FORMING IMAGE | FUJIFILM CORPORATION (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090043081-A1 | INK JET RECORDING SET AND INK JET RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20080125411-A1 | DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2008-05-29 | — | — | US | disclosed |
| EP-1859793-A1 | NOVEL COMBINATIONAL USE OF SULFONAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-11-28 | — | — | EP | disclosed |
| US-7217447-B2 | Ink-jet recording sheet | FUJIFILM CORPORATION (JP) | 2007-05-15 | — | — | US | disclosed |
| EP-1709965-A2 | Methods of treating cytokine mediate diseases | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2006-10-11 | — | — | EP | disclosed |
| US-6916814-B2 | Methods of treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-5770599-A | RECEPTOR TYROSINE KINASE INHIBITORS including 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(2-morpholinoethoxy)quinazoline (gefitinib) | ZENECA LIMITED (GB) | 1998-06-23 | — | — | US | disclosed |
| EP-0823900-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-02-18 | — | — | EP | disclosed |
| WO-1996033980-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EGFR, KIT, ERBB2 | ALDH1A1 3259/4885KDM4E 2562/4885KMT2A 755/4885 |
| US-20080125411-A1 | DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS | DHODH, THPO, SQLE | ALDH1A1 319/4885KDM4E 3438/4885KMT2A 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.